A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Phytocannabinoids that do not produce psychotropic effects are considered of special interest as novel therapeutic agents in CNS diseases. A cannabigerol quinone, the compound VCE-003, has been shown to alleviate symptoms in a viral model of multiple sclerosis (MS). Hence, we studied T cells and macrophages as targets for VCE-003 and its efficacy in an autoimmune model of MS. Proliferation, cell cycle, expression of activation markers was assessed by FACs in human primary T cells, and cytokine and chemokine production was evaluated. Transcription was studied in Jurkat cells and RAW264.7 cells were used to study the effects of VCE-003 on IL-17-induced macrophage polarization to a M1 phenotype. Experimental autoimmune encephalomyelitis (EAE) was induced by myelin oligodendrocyte glycoprotein (MOG₃₅₋₅₅) immunization and spinal cord pathology was assessed by immunohistochemistry. Neurological impairment was evaluated using disease scores. We show here that VCE-003 inhibits CD3/CD28-induced proliferation, cell cycle progression and the expression of the IL-2Rα and ICAM-1 activation markers in human primary T cells. VCE-003 inhibits the secretion of Th1/Th17 cytokines and chemokines in primary murine T cells, and it reduces the transcriptional activity of the IL-2, IL-17 and TNFα promoters induced by CD3/CD28. In addition, VCE-003 and JWH-133, a selective CB2 agonist, dampened the IL-17-induced polarization of macrophages to a pro-inflammatory M1 profile. VCE-003 also prevented LPS-induced iNOS expression in microglia. VCE-003 ameliorates the neurological defects and the severity of MOG-induced EAE in mice through CB2 and PPARγ receptor activation. A reduction in cell infiltrates, mainly CD4+ T cells, was observed, and Th1 and Th17 responses were inhibited in the spinal cord of VCE-003-treated mice, accompanied by weaker microglial activation, structural preservation of myelin sheets and reduced axonal damage. This study highlights the therapeutic potential of VCE-003 as an agent for the treatment of human immune diseases with both inflammatory and autoimmune components.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 16×
“Phytocannabinoids that do not produce psychotropic effects are considered of special interest as novel therapeutic agents in CNS diseases.”
BackgroundInfluentialIL-17 plays an important role in the development of experimental autoimmune encephalomyelitis
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., & Iwakura, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.566 · Cited by 1,536
Experimental autoimmune encephalomyelitis repressed by microglial paralysis
Heppner, F. L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., Waisman, A., Rülicke, T., Prinz, M., Priller, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1177 · Cited by 732 · cited 1×
“In the EAE model, nervous tissue inflammation is characterized by the activation of microglia [4,5], which may amplify damage by releasing mediators of toxicity and cytokines.”
BackgroundCellular mechanisms of IL-17-induced blood-brain barrier disruption
Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., Bechmann, I., Becher, B., Luhmann, H. J., Waisman, A., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-141978 · Cited by 529 · cited 16×
“Phytocannabinoids that do not produce psychotropic effects are considered of special interest as novel therapeutic agents in CNS diseases.”
BackgroundInfluentialHuitinga, I., van Rooijen, N., de Groot, C. J., Uitdehaag, B. M., & Dijkstra, C. D. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.4.1025 · Cited by 506 · cited 1×
“the progression of MS and EAE [5,25].”
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · cited 1×
“[7], are considered of special interest as novel therapeutic agents in CNS diseases.”
BackgroundIL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence
Datta, S., Novotny, M., Pavicic, P. G., Zhao, C., Herjan, T., Hartupee, J., & Hamilton, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902423 · Cited by 82 · cited 1×
“If this were the case, IL-17 released in CD3/CD28-stimulated T cells could act in an autocrine manner, increasing the stability of other CD3/CD28induced cytokine mRNAs, an activity that could also be inhibited by VCE-003 [30,31].”
Background
Cited by
Phytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Endocannabinoids drive the acquisition of an alternative phenotype in microglia
Mecha, M., Feliú, A., Carrillo-Salinas, F. J., Rueda-Zubiaurre, A., Ortega-Gutiérrez, S., de Sola, R. G., & Guaza, C. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.002 · Cited by 234
Self-citationCalina, D., Buga, A. M., Mitroi, M., Buha, A., Caruntu, C., Scheau, C., Bouyahya, A., El Omari, N., El Menyiy, N., & Docea, A. O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082395 · Cited by 65
Guadalupi, L., Mandolesi, G., Vanni, V., Balletta, S., Caioli, S., Pavlovic, A., De Vito, F., Fresegna, D., Sanna, K., Vitiello, L., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109940 · Cited by 22
“Cannabinoid agonists have been shown to reduce the clinical severity of murine models of EAE and were associated with decreased microglia/macrophage activation in the CNS (Kozela et al., 2011; Carrillo-Salinas et al., 2014; Rahimi et al., 2015).”
Metadata
- Authors
- Carrillo-Salinas, F. J., Navarrete, C., Mecha, M., Feliú, A., Collado, J. A., Cantarero, I., Bellido, M. L., Muñoz, E., & Guaza, C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-11
- Volume
- 9
- Issue
- 4
- Pages
- e94733
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2155932375
- Cited by
- 66
- References
- 9
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis. https://app.cochat.ai/papers/10.1371/journal.pone.0094733
- The paper
- Carrillo-Salinas, F. J., Navarrete, C., Mecha, M., Feliú, A., Collado, J. A., Cantarero, I., Bellido, M. L., Muñoz, E., & Guaza, C. (2014). A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis. PLoS ONE. https://doi.org/10.1371/journal.pone.0094733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.